Figure 3.

Further analysis of the hit compounds and others in a concentration-dependent manner.

A, Nafamostat mesylate, a known complement inhibitor, was independently identified using our screening method. B-D, Our screening method identified three new complement activation inhibitors—cisplatin, pyridostatin, and cDPCP. All three compounds inhibit complement activation in a concentration-dependent manner. E-F, Cisplatin and pyridostatin inhibit the classical pathway (CP) of complement activation in a sensitized sheep erythrocyte (E^shA)-based hemolysis assay (upper panels), but not in the alternative pathway (AP) in a rabbit erythrocyte (E^rabb)-based hemolysis assay (lower panels). G-H. Two other platinum-containing agents, oxaliplatin and carboplatin, do not inhibit complement activation. All experiments were performed in duplicate, and the results are shown as mean ± standard deviations from one representative experiment. NHS, normal human serum.